Scynexis (SCYX) Assets Average (2014 - 2026)
Scynexis' (SCYX) quarterly Assets Average came in at $76.3 million in Q2 2026, up 18.65% on a YoY basis from $64.3 million in Q2 2025, and up 11.67% quarter-over-quarter from $68.3 million in Q1 2026.
Analysis
Scynexis (SCYX) Assets Average (2014 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Assets Average for 13 consecutive years, with $76.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average rose 18.65% year-over-year to $76.3 million; the trailing twelve-month figure through Jun 2026 stood at $76.3 million (up 18.65% YoY), and the FY2025 full-year result was $74.8 million, down 31.67% from the prior year.
- Assets Average improved to $76.3 million in Q2 2026 per SCYX's latest filing, from $68.3 million in the prior quarter.
- Across five years, Assets Average topped out at $151.7 million in Q3 2023 and bottomed at $55.0 million in Q4 2025.
- Historically, Assets Average has averaged $98.8 million across 5 years, with a median of $101.7 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Assets Average soared 56.01% in 2024, then tumbled 45.97% in 2025.
- Over 5 years, Assets Average stood at $100.1 million in 2022, then jumped by 38.41% to $138.5 million in 2023, then tumbled by 31.51% to $94.8 million in 2024, then tumbled by 41.96% to $55.0 million in 2025, then jumped by 38.6% to $76.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $76.3 million, $68.3 million, and $55.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 76.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 76.30 Mn |
| Mar 31, 2026 | 68.33 Mn |
| Dec 31, 2025 | 55.05 Mn |
| Sep 30, 2025 | 55.88 Mn |
| Jun 30, 2025 | 64.30 Mn |
| Mar 31, 2025 | 79.28 Mn |
| Dec 31, 2024 | 94.84 Mn |
| Sep 30, 2024 | 103.42 Mn |
| Jun 30, 2024 | 113.03 Mn |
| Mar 31, 2024 | 123.33 Mn |
| Dec 31, 2023 | 138.48 Mn |
| Sep 30, 2023 | 151.70 Mn |
| Jun 30, 2023 | 112.58 Mn |
| Mar 31, 2023 | 79.05 Mn |
| Dec 31, 2022 | 100.05 Mn |
| Sep 30, 2022 | 123.95 Mn |
| Jun 30, 2022 | 123.59 Mn |
| Mar 31, 2022 | 115.70 Mn |
| Dec 31, 2021 | 114.86 Mn |
| Sep 30, 2021 | 115.51 Mn |